Galecto Inc (GLTO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galecto Inc (GLTO) has a cash flow conversion efficiency ratio of -0.040x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.60 Million) by net assets ($510.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Galecto Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Galecto Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Galecto Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Galecto Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galecto Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kemper Corporation
NYSE:KMPR
|
0.034x |
|
Jiangsu Zhangjiagang Rural Commercial Bank Co Ltd
SHE:002839
|
0.253x |
|
La-Z-Boy Incorporated
NYSE:LZB
|
0.085x |
|
Southern Publishing&Media Co
SHG:601900
|
0.007x |
|
Sayona Mining Limited American Depository Shares
NASDAQ:ELVR
|
-0.060x |
|
Hisense Home Appliances Group Co. Ltd
F:GKE
|
0.212x |
|
Deutsche EuroShop AG
F:DEQ
|
0.014x |
|
China Resources Chemical Innovative Materials Co. Ltd.
SHE:301090
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Galecto Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Galecto Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Galecto Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $240.38 Million | $-6.73 Million | -0.028x | +97.62% |
| 2024-12-31 | $15.83 Million | $-18.62 Million | -1.176x | -3.04% |
| 2023-12-31 | $32.33 Million | $-36.91 Million | -1.142x | -64.22% |
| 2022-12-31 | $61.75 Million | $-42.93 Million | -0.695x | -55.80% |
| 2021-12-31 | $117.22 Million | $-52.31 Million | -0.446x | -93.30% |
| 2020-12-31 | $165.49 Million | $-38.20 Million | -0.231x | +42.10% |
| 2019-12-31 | $48.47 Million | $-19.33 Million | -0.399x | +10.71% |
| 2018-12-31 | $30.66 Million | $-13.69 Million | -0.447x | -- |
About Galecto Inc
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The comp… Read more